JP4671955B2 - Ｃｒｔｈ２によって媒介される病気の治療に有用なピリミジン誘導体 - Google Patents

Ｃｒｔｈ２によって媒介される病気の治療に有用なピリミジン誘導体 Download PDF

Info

Publication number
JP4671955B2
JP4671955B2 JP2006505114A JP2006505114A JP4671955B2 JP 4671955 B2 JP4671955 B2 JP 4671955B2 JP 2006505114 A JP2006505114 A JP 2006505114A JP 2006505114 A JP2006505114 A JP 2006505114A JP 4671955 B2 JP4671955 B2 JP 4671955B2
Authority
JP
Japan
Prior art keywords
amino
benzyl
acetic acid
dimethylamino
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006505114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524645A (ja
JP2006524645A5 (enExample
Inventor
リュウ タイ−ウエイ
コリヤマ ユウジ
ヨシノ タカシ
サトウ ヒロキ
タナカ カズホ
スギモト ヒロミ
マナベ ヨシヒサ
バコン ケビン
ウルバハンス クジャウス
セキ マサノリ
シンタニ タクヤ
Original Assignee
アクチミス ファーマシューティカルズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクチミス ファーマシューティカルズ インコーポレーテッド filed Critical アクチミス ファーマシューティカルズ インコーポレーテッド
Publication of JP2006524645A publication Critical patent/JP2006524645A/ja
Publication of JP2006524645A5 publication Critical patent/JP2006524645A5/ja
Application granted granted Critical
Publication of JP4671955B2 publication Critical patent/JP4671955B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006505114A 2003-04-25 2004-04-14 Ｃｒｔｈ２によって媒介される病気の治療に有用なピリミジン誘導体 Expired - Fee Related JP4671955B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
PCT/EP2004/003910 WO2004096777A1 (en) 2003-04-25 2004-04-14 Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010249273A Division JP5161290B2 (ja) 2003-04-25 2010-11-08 Ｃｒｔｈ２によって媒介される病気の治療に有用なピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2006524645A JP2006524645A (ja) 2006-11-02
JP2006524645A5 JP2006524645A5 (enExample) 2007-06-07
JP4671955B2 true JP4671955B2 (ja) 2011-04-20

Family

ID=32946880

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006505114A Expired - Fee Related JP4671955B2 (ja) 2003-04-25 2004-04-14 Ｃｒｔｈ２によって媒介される病気の治療に有用なピリミジン誘導体
JP2010249273A Expired - Fee Related JP5161290B2 (ja) 2003-04-25 2010-11-08 Ｃｒｔｈ２によって媒介される病気の治療に有用なピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010249273A Expired - Fee Related JP5161290B2 (ja) 2003-04-25 2010-11-08 Ｃｒｔｈ２によって媒介される病気の治療に有用なピリミジン誘導体

Country Status (32)

Country Link
US (2) US7812160B2 (enExample)
EP (2) EP1471057B1 (enExample)
JP (2) JP4671955B2 (enExample)
KR (1) KR101110491B1 (enExample)
CN (2) CN101914065A (enExample)
AR (1) AR043885A1 (enExample)
AT (2) ATE316077T1 (enExample)
AU (1) AU2004233966B2 (enExample)
BR (1) BRPI0409733A (enExample)
CA (1) CA2523439C (enExample)
CL (1) CL43596B (enExample)
CY (1) CY1111295T1 (enExample)
DE (2) DE60303238T2 (enExample)
DK (2) DK1471057T3 (enExample)
DO (1) DOP2004000875A (enExample)
ES (2) ES2257616T3 (enExample)
GT (1) GT200400079A (enExample)
HN (1) HN2004000129A (enExample)
IL (1) IL171566A (enExample)
MX (1) MXPA05011399A (enExample)
MY (1) MY147984A (enExample)
NO (1) NO20055588L (enExample)
NZ (1) NZ543693A (enExample)
PE (1) PE20050143A1 (enExample)
PL (1) PL1633726T3 (enExample)
PT (2) PT1471057E (enExample)
RU (1) RU2361865C2 (enExample)
SI (1) SI1633726T1 (enExample)
TW (1) TWI353980B (enExample)
UY (1) UY28286A1 (enExample)
WO (1) WO2004096777A1 (enExample)
ZA (1) ZA200508722B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
ATE316077T1 (de) 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
EP3718564B1 (en) * 2003-12-23 2023-10-11 Genentech, Inc. Novel anti-il 13 antibodies and uses thereof
EP1718649B1 (en) 2004-01-31 2009-06-10 Actimis Pharmaceuticals, Inc., Imidazo 1,2-c pyrimidinylacetic acid derivatives
ES2304010T3 (es) 2004-03-11 2008-09-01 Actelion Pharmaceuticals Ltd. Derivados de tetrahidropiridoindol.
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
DK1871374T3 (da) 2005-04-21 2011-12-05 Merck Serono Sa 2,3-substituerede pyrazinsulfonamider som CRTH2-inhibitorer
MX2007014256A (es) 2005-05-24 2008-03-26 Serono Lab Derivados espiro triciclicos como moduladores crth2.
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
AU2007256597A1 (en) * 2006-06-09 2007-12-13 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
EP2132196A1 (en) * 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CN101772489B (zh) * 2007-06-21 2013-02-20 艾克提麦斯医药品有限公司 一种crth2拮抗剂的胺盐
CN103172573A (zh) * 2007-06-21 2013-06-26 艾克提麦斯医药品有限公司 Crth2 拮抗剂的微粒
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
ATE547407T1 (de) * 2007-09-25 2012-03-15 Actimis Pharmaceuticals Inc Alkylthiopyrimidine als crth2-antagonisten
AU2008305633B2 (en) * 2007-09-25 2013-09-12 Actimis Pharmaceuticals, Inc. 2-S-benzyl substituted pyrimidines as CRTH2 antagonists
EP2257524B1 (en) 2008-02-01 2016-01-06 Brickell Biotech, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
JP2011518130A (ja) 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト
WO2010003120A2 (en) 2008-07-03 2010-01-07 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
JP5586606B2 (ja) * 2008-09-02 2014-09-10 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストとしての同位体富化されたピリミジン−５−イル酢酸誘導体
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
JPWO2010074244A1 (ja) * 2008-12-25 2012-06-21 大正製薬株式会社 イソキノリン誘導体
WO2010089391A1 (en) 2009-02-09 2010-08-12 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
AU2010212970A1 (en) 2009-02-12 2011-08-18 Merck Serono S.A. Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
CA2768587A1 (en) 2009-08-05 2011-02-10 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
MX2012006003A (es) * 2009-11-24 2012-06-19 Boehringer Ingelheim Int Procedimiento para preparar un polimorfo de la sal de colina de [4,6-bis(dimetilamino)-2-(4-{[4-(trifluorometil)-benzoil]amino}be ncil)pirimidin-5-ilo].
CA2782085A1 (en) 2010-01-06 2011-07-14 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
AU2011209286B2 (en) 2010-01-27 2016-02-11 Gb007, Inc. Pyrazole compounds as CRTH2 antagonists
CN103119024A (zh) 2010-06-23 2013-05-22 大正制药株式会社 异喹啉衍生物
EP2590944B1 (en) 2010-07-05 2015-09-30 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2598145A1 (en) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical composition for treatment of respiratory and inflammatory diseases
WO2012013566A1 (en) 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
WO2012054691A2 (en) 2010-10-20 2012-04-26 Valspar Sourcing, Inc. Water-based coating system with improved adhesion to a wide range of coated and uncoated substrates including muffler grade stainless steel
EP2640705A2 (en) 2010-11-15 2013-09-25 Katholieke Universiteit Leuven Novel antiviral compounds
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
TWI527809B (zh) 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
JP5999387B2 (ja) 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｒｔｈ２拮抗薬としてのピラゾール化合物
RS56326B1 (sr) * 2011-05-16 2017-12-29 Actimis Pharmaceuticals Inc Postupak za pripremu [4,6-bis-dimetilamino-2-[4-(4-trifluorometilbenzoil-amino)benzil]pirimidin-5-il]sirćetne kiseline
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
ES2624379T3 (es) 2011-12-21 2017-07-14 Idorsia Pharmaceuticals Ltd Derivados de heterociclilo y su uso como moduladores del receptor de prostaglandina D2
US9169270B2 (en) 2012-07-05 2015-10-27 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
US20140148470A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en) * 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
CA2263198A1 (en) * 1996-09-06 1998-03-12 Nippon Kayaku Kabushiki Kaisha Novel acetamide derivatives and protease inhibitors
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
CA2408727A1 (en) * 2000-05-22 2001-11-29 Leo Pharma A/S Benzophenones as inhibitors of il-1.beta. and tnf-.alpha.
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
ATE316077T1 (de) 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
CN103172573A (zh) 2007-06-21 2013-06-26 艾克提麦斯医药品有限公司 Crth2 拮抗剂的微粒
CN101772489B (zh) 2007-06-21 2013-02-20 艾克提麦斯医药品有限公司 一种crth2拮抗剂的胺盐

Also Published As

Publication number Publication date
HK1095320A1 (en) 2007-05-04
AR043885A1 (es) 2005-08-17
PT1633726E (pt) 2011-02-22
HN2004000129A (es) 2009-05-14
NO20055588D0 (no) 2005-11-25
GT200400079A (es) 2004-11-30
DK1633726T3 (da) 2011-03-28
NZ543693A (en) 2009-05-31
CN1809539A (zh) 2006-07-26
RU2361865C2 (ru) 2009-07-20
EP1471057A1 (en) 2004-10-27
AU2004233966A1 (en) 2004-11-11
MY147984A (en) 2013-02-28
KR20060089622A (ko) 2006-08-09
TW200505873A (en) 2005-02-16
US20100322980A1 (en) 2010-12-23
AU2004233966B2 (en) 2010-11-11
CN1809539B (zh) 2012-05-09
ATE494279T1 (de) 2011-01-15
WO2004096777A1 (en) 2004-11-11
ES2358424T3 (es) 2011-05-10
PL1633726T3 (pl) 2011-06-30
RU2005136655A (ru) 2006-06-10
DE602004030907D1 (de) 2011-02-17
EP1471057B1 (en) 2006-01-18
DE60303238T2 (de) 2006-09-14
EP1633726B1 (en) 2011-01-05
DK1471057T3 (da) 2006-05-15
JP2006524645A (ja) 2006-11-02
DOP2004000875A (es) 2004-10-31
JP2011068657A (ja) 2011-04-07
US7812160B2 (en) 2010-10-12
UY28286A1 (es) 2004-11-30
CY1111295T1 (el) 2015-08-05
PT1471057E (pt) 2006-05-31
ZA200508722B (en) 2006-12-27
CL43596B (es) 2005-03-18
MXPA05011399A (es) 2006-05-31
TWI353980B (en) 2011-12-11
CA2523439C (en) 2012-06-19
JP5161290B2 (ja) 2013-03-13
CN101914065A (zh) 2010-12-15
EP1633726A1 (en) 2006-03-15
DE60303238D1 (de) 2006-04-06
ES2257616T3 (es) 2006-08-01
KR101110491B1 (ko) 2012-01-31
US20070129355A1 (en) 2007-06-07
CA2523439A1 (en) 2004-11-11
PE20050143A1 (es) 2005-04-01
US7960393B2 (en) 2011-06-14
SI1633726T1 (sl) 2011-04-29
NO20055588L (no) 2006-01-24
ATE316077T1 (de) 2006-02-15
IL171566A (en) 2011-03-31
BRPI0409733A (pt) 2006-05-09

Similar Documents

Publication Publication Date Title
JP4671955B2 (ja) Ｃｒｔｈ２によって媒介される病気の治療に有用なピリミジン誘導体
JP4996257B2 (ja) イミダゾ［１，２−ｃ］ピリミジニル酢酸誘導体
US20030139435A1 (en) N-heterocyclic inhibitors of TNF-alpha expression
EP1654237A1 (en) 2-aminopyrimidine derivatives
HK1095320B (en) Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101221

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110118

R150 Certificate of patent or registration of utility model

Ref document number: 4671955

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140128

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees